智通财经APP获悉，中金发布研究报告称，维持科伦博泰生物-B(06990)“跑赢行业”评级，上调集团目标价9.5%至230港元。集团另有“芦康沙妥珠单抗单”药治疗EGFR-TKI经治（2L）及EGFR-TKI及含铂化疗经治（3L）的非小细胞肺癌（NSCLC）上市申请，已获国家药监局受理，该行预计有望在2025年获批上市。
报告中称，由于科伦博泰生物核心产品“芦康沙妥珠单抗”(sac-TMT)获批上市，该行认为，该产品的临床数据具有竞争力，或为内地患者带来新的治疗选择。同时调整风险因子及考虑到商业化节奏良好，上调集团明年收入预测11.1%至11.4亿元人民币。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.